StockData

Liminatus Pharma, Inc. (LIMN) stock

LIMNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as LIMNW
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 2/30
$2.99+0.22 (+7.94%)

Close on Nov 13, 2026Market cap $200.81MP/E –Yield –

Liminatus Pharma ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

No ebitda figures for Liminatus Pharma

Liminatus Pharma has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Liminatus Pharma figures

See a number that looks wrong?